Osimertinib Plus Chemotherapy Shows Superior Results Versus Osimertinib Alone For Egfr-Mutated A...

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated a...

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJM

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

Osimertinib + ipilimumab in EGFR-mutated NSCLC

Dr. Wakelee on Rationale to Explore Osimertinib With Concurrent Chemotherapy in EGFR-Mutant NSCLC

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2

European Society for Medical Oncology (ESMO)

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

Future Science Group

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

Treatment Options: Newly Diagnosed EGFR+ NSCLC

Targeted Oncology

TATTON trial – Savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC | Lecia Sequist

Medicine Matters oncology

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

Future Science Group

Emerging treatment strategies in EGFR-mutant NSCLC: osimertinib combinations and beyond

FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib

Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-...

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancer

ESMO 2020 Highlights on adjuvant osimertinib for EGFR mutated NSCLC: The ADAURA study

European Society for Medical Oncology (ESMO)

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

FLAURA study: a new standard of care for patients with EGFR mutated NSCLC

Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer